JP2008517926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517926A5 JP2008517926A5 JP2007538060A JP2007538060A JP2008517926A5 JP 2008517926 A5 JP2008517926 A5 JP 2008517926A5 JP 2007538060 A JP2007538060 A JP 2007538060A JP 2007538060 A JP2007538060 A JP 2007538060A JP 2008517926 A5 JP2008517926 A5 JP 2008517926A5
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- phenyl
- carboxylic acid
- amide
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XTDRPNJABDWQFI-UHFFFAOYSA-N 5-cyano-1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC(C#N)=CN1 XTDRPNJABDWQFI-UHFFFAOYSA-N 0.000 claims 64
- -1 chloro, fluoro, methyl Chemical group 0.000 claims 56
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003277 amino group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000002883 imidazolyl group Chemical group 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 4
- SAEZQFNKTQKVSM-UHFFFAOYSA-N 4-cyano-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC(C#N)=CN1 SAEZQFNKTQKVSM-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- LJVQHXICFCZRJN-UHFFFAOYSA-N 1h-1,2,4-triazole-5-carboxylic acid Chemical compound OC(=O)C1=NC=NN1 LJVQHXICFCZRJN-UHFFFAOYSA-N 0.000 claims 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- GDCBIQJUSRDOGR-UHFFFAOYSA-N 5-chloro-1h-1,2,4-triazole-3-carboxylic acid Chemical compound OC(=O)C1=NNC(Cl)=N1 GDCBIQJUSRDOGR-UHFFFAOYSA-N 0.000 claims 2
- IRZATOLKYBKBAO-UHFFFAOYSA-N 5-cyano-n-[2-(1,1-dioxo-3,6-dihydro-2h-thiopyran-4-yl)-4-piperidin-4-ylphenyl]-1h-imidazole-2-carboxamide Chemical compound N=1C(C#N)=CNC=1C(=O)NC1=CC=C(C2CCNCC2)C=C1C1=CCS(=O)(=O)CC1 IRZATOLKYBKBAO-UHFFFAOYSA-N 0.000 claims 2
- FVYYZAZCLYZXQC-UHFFFAOYSA-N 5-cyano-n-[2-(2-fluorophenyl)-4-(4-methylpiperazin-1-yl)phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1C(C=C1C=2C(=CC=CC=2)F)=CC=C1NC(=O)C1=CC=C(C#N)O1 FVYYZAZCLYZXQC-UHFFFAOYSA-N 0.000 claims 2
- GXQMEGDUUBFCFH-UHFFFAOYSA-N 5-cyano-n-[2-(2-methylphenyl)-4-(4-methylpiperazin-1-yl)phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1C(C=C1C=2C(=CC=CC=2)C)=CC=C1NC(=O)C1=CC=C(C#N)O1 GXQMEGDUUBFCFH-UHFFFAOYSA-N 0.000 claims 2
- IIYSPOQOLUOWON-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-(1,3-dihydroxypropan-2-yl)piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CN(C(CO)CO)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 IIYSPOQOLUOWON-UHFFFAOYSA-N 0.000 claims 2
- ZDZWIYNKACEWQC-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-(1h-imidazol-5-yl)acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CC(C=2C=C(C(NC(=O)C=3NC=C(N=3)C#N)=CC=2)C=2CCCCC=2)CCN1C(=O)CC1=CN=CN1 ZDZWIYNKACEWQC-UHFFFAOYSA-N 0.000 claims 2
- JJZWAMOLUCACLS-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-[2-hydroxyethyl(methyl)amino]acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CN(C(=O)CN(CCO)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 JJZWAMOLUCACLS-UHFFFAOYSA-N 0.000 claims 2
- WQWMJNBXEBZCOT-UHFFFAOYSA-N 5-cyano-n-[2-(cyclopenten-1-yl)-4-[1-[(1-methylimidazol-2-yl)methyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound CN1C=CN=C1CN1CCC(C=2C=C(C(NC(=O)C=3NC=C(N=3)C#N)=CC=2)C=2CCCC=2)CC1 WQWMJNBXEBZCOT-UHFFFAOYSA-N 0.000 claims 2
- FXFXHNQBLWHYDI-UHFFFAOYSA-N 5-cyano-n-[2-(cyclopenten-1-yl)-4-piperidin-4-ylphenyl]-1h-imidazole-2-carboxamide Chemical compound N=1C(C#N)=CNC=1C(=O)NC1=CC=C(C2CCNCC2)C=C1C1=CCCC1 FXFXHNQBLWHYDI-UHFFFAOYSA-N 0.000 claims 2
- ZWRCMAAVANOLOT-UHFFFAOYSA-N 5-cyano-n-[4-(4-methylpiperazin-1-yl)-2-(2-methylthiophen-3-yl)phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1C(C=C1C2=C(SC=C2)C)=CC=C1NC(=O)C1=CC=C(C#N)O1 ZWRCMAAVANOLOT-UHFFFAOYSA-N 0.000 claims 2
- BKGAAMAFOWYKJB-UHFFFAOYSA-N 5-cyano-n-[4-(4-methylpiperazin-1-yl)-2-(3-methylthiophen-2-yl)phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1C(C=C1C2=C(C=CS2)C)=CC=C1NC(=O)C1=CC=C(C#N)O1 BKGAAMAFOWYKJB-UHFFFAOYSA-N 0.000 claims 2
- HHHCADSYQQJUGV-UHFFFAOYSA-N 5-cyanofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)O1 HHHCADSYQQJUGV-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000037408 Device failure Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000037099 Prosthesis Failure Diseases 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VHOZQGFKMQDWHA-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)-2-(1,1-dioxo-3,6-dihydro-2h-thiopyran-4-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1C=2CCS(=O)(=O)CC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 VHOZQGFKMQDWHA-UHFFFAOYSA-N 0.000 claims 2
- GCPYRLIYCNLRAT-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)-2-(1,2,3,6-tetrahydropyridin-5-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1C=2CNCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 GCPYRLIYCNLRAT-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- VTVVSHJUELMWBZ-UHFFFAOYSA-N 5-cyano-n-[2-(3,6-dihydro-2h-pyran-4-yl)-4-(4-methylpiperazin-1-yl)phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1C(C=C1C=2CCOCC=2)=CC=C1NC(=O)C1=CC=C(C#N)O1 VTVVSHJUELMWBZ-UHFFFAOYSA-N 0.000 claims 1
- YEEBLJFZYXYIOQ-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-(2-morpholin-4-ylacetyl)piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CC(C=2C=C(C(NC(=O)C=3NC=C(N=3)C#N)=CC=2)C=2CCCCC=2)CCN1C(=O)CN1CCOCC1 YEEBLJFZYXYIOQ-UHFFFAOYSA-N 0.000 claims 1
- YVQZJJDQRBMAQM-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-(1-methylimidazol-4-yl)acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound CN1C=NC(CC(=O)N2CCC(CC2)C=2C=C(C(NC(=O)C=3NC=C(N=3)C#N)=CC=2)C=2CCCCC=2)=C1 YVQZJJDQRBMAQM-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- FFASJWSCBGYXQX-UHFFFAOYSA-N n-[4-[1-(2-amino-2-methylpropanoyl)piperidin-4-yl]-2-(cyclohexen-1-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.C1CN(C(=O)C(C)(N)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC=C(C#N)N1 FFASJWSCBGYXQX-UHFFFAOYSA-N 0.000 claims 1
- WVJQGZYKOZGBMB-UHFFFAOYSA-N n-[4-[1-(3-amino-3-methylbutanoyl)piperidin-4-yl]-2-(cyclohexen-1-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.C1CN(C(=O)CC(C)(N)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 WVJQGZYKOZGBMB-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000009103 reabsorption Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C*(CCN(C)C1(C)O)C1(*)O Chemical compound C*(CCN(C)C1(C)O)C1(*)O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62121104P | 2004-10-22 | 2004-10-22 | |
| US60/621,211 | 2004-10-22 | ||
| PCT/US2005/037868 WO2006047277A2 (en) | 2004-10-22 | 2005-10-20 | Inhibitors of c-fms kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008517926A JP2008517926A (ja) | 2008-05-29 |
| JP2008517926A5 true JP2008517926A5 (https=) | 2008-12-04 |
| JP5046950B2 JP5046950B2 (ja) | 2012-10-10 |
Family
ID=36228272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538060A Expired - Fee Related JP5046950B2 (ja) | 2004-10-22 | 2005-10-20 | Ｃ−ｆｍｓキナーゼのインヒビター |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1807077B1 (https=) |
| JP (1) | JP5046950B2 (https=) |
| KR (1) | KR101273434B1 (https=) |
| CN (1) | CN101437514B (https=) |
| AU (1) | AU2005299837A1 (https=) |
| BR (1) | BRPI0516947A (https=) |
| CA (1) | CA2585053C (https=) |
| DK (1) | DK1807077T3 (https=) |
| EA (1) | EA013250B1 (https=) |
| ES (1) | ES2611604T3 (https=) |
| HU (1) | HUE033089T2 (https=) |
| MX (1) | MX2007004784A (https=) |
| NO (1) | NO339555B1 (https=) |
| PL (1) | PL1807077T3 (https=) |
| PT (1) | PT1807077T (https=) |
| UA (1) | UA88648C2 (https=) |
| WO (1) | WO2006047277A2 (https=) |
| ZA (1) | ZA200704106B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7427683B2 (en) | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
| US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
| MXPA05011503A (es) | 2003-04-25 | 2006-05-31 | Johnson & Johnson | Inhibidores de la c-fms cinasa. |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| WO2006047504A1 (en) * | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Aromatic amides as inhibitors of c-fms kinase |
| JP4058106B2 (ja) | 2005-02-18 | 2008-03-05 | アストラゼネカ アクチボラグ | 抗菌性のピペリジン誘導体 |
| CN101171247A (zh) * | 2005-03-04 | 2008-04-30 | 阿斯利康(瑞典)有限公司 | 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物 |
| JP2008540665A (ja) | 2005-05-19 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なビアリール |
| JP5388574B2 (ja) | 2005-05-31 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なヘテロ環式類 |
| US20070004660A1 (en) * | 2005-06-10 | 2007-01-04 | Baumann Christian A | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
| US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| AU2006304897B2 (en) | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
| WO2007124319A1 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| PL2021335T3 (pl) | 2006-04-20 | 2011-10-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory kinazy C-FMS |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| CA2649755C (en) | 2006-04-20 | 2014-12-02 | Janssen Pharmaceutica N.V. | Method of inhibiting c-kit kinase |
| JP2009534380A (ja) * | 2006-04-20 | 2009-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼインヒビター |
| EP2152271B1 (en) | 2007-06-08 | 2015-10-21 | Janssen Pharmaceutica, N.V. | Piperidine/piperazine derivatives |
| JP5464709B2 (ja) | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン／ピペラジン誘導体 |
| ES2536406T3 (es) | 2007-06-08 | 2015-05-25 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| AU2013203813B2 (en) * | 2007-10-17 | 2014-07-31 | Janssen Pharmaceutica, N.V. | Inhibitors of C-FMS kinase |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| AU2008318854A1 (en) * | 2007-11-02 | 2009-05-07 | Janssen Pharmaceutica, N.V. | Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| PE20100083A1 (es) | 2008-06-05 | 2010-02-17 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
| WO2011149841A1 (en) | 2010-05-25 | 2011-12-01 | Janssen Pharmaceutica Nv | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS |
| WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| ES2658773T3 (es) | 2012-08-07 | 2018-03-12 | Janssen Pharmaceutica N.V. | Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo |
| WO2014041106A1 (en) * | 2012-09-17 | 2014-03-20 | F. Hoffmann-La Roche Ag | Triazole carboxamide derivatives |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103804349A (zh) * | 2012-11-01 | 2014-05-21 | 杨子娇 | 一类治疗青光眼的化合物及其用途 |
| CN104370880A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
| CN104370882A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类降低眼压的化合物及其制备方法和用途 |
| CN104370881A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类具有神经保护作用的化合物及其制备方法和用途 |
| WO2014151258A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Substituted pyridine derivatives useful as c-fms kinase inhibitors |
| JP6330040B2 (ja) | 2013-07-22 | 2018-05-23 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−（ピペラジン−１−イル）−２−（［１，２，４］トリアゾール−１−イル）−エタノン誘導体 |
| EP3044221B1 (en) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| PL3245203T3 (pl) | 2015-01-15 | 2019-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3 |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| CN109134429B (zh) * | 2017-08-10 | 2021-06-01 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| US10930064B2 (en) | 2018-02-08 | 2021-02-23 | Covidien Lp | Imaging reconstruction system and method |
| WO2020127200A1 (en) | 2018-12-17 | 2020-06-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
| WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
| CN121729411A (zh) * | 2023-06-09 | 2026-03-24 | 模杜罗生物公司 | 作为csf1r抑制剂的5-氰基-1h-咪唑-2-甲酰胺化合物 |
| WO2026010948A1 (en) | 2024-07-01 | 2026-01-08 | Otsuka America Pharmaceutical, Inc. | Compounds useful for the treatment of disorders and methods related thereto |
| WO2026030444A1 (en) | 2024-07-30 | 2026-02-05 | Otsuka America Pharmaceutical, Inc | Compounds useful for the treatment of disorders and methods related thereto |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| CA2336848A1 (en) * | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| US6383790B1 (en) * | 1999-01-11 | 2002-05-07 | Princeton University | High affinity protein kinase inhibitors |
| EP1246823A1 (en) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| CA2486183C (en) * | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
| AU2003282726B2 (en) * | 2002-10-03 | 2010-10-07 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| US20050113566A1 (en) * | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
| MXPA05011503A (es) * | 2003-04-25 | 2006-05-31 | Johnson & Johnson | Inhibidores de la c-fms cinasa. |
| WO2006047504A1 (en) * | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Aromatic amides as inhibitors of c-fms kinase |
| AU2006304897B2 (en) * | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
-
2005
- 2005-10-20 PT PT58153610T patent/PT1807077T/pt unknown
- 2005-10-20 KR KR1020077011145A patent/KR101273434B1/ko not_active Expired - Fee Related
- 2005-10-20 CN CN2005800435040A patent/CN101437514B/zh not_active Expired - Fee Related
- 2005-10-20 WO PCT/US2005/037868 patent/WO2006047277A2/en not_active Ceased
- 2005-10-20 EP EP05815361.0A patent/EP1807077B1/en not_active Expired - Lifetime
- 2005-10-20 JP JP2007538060A patent/JP5046950B2/ja not_active Expired - Fee Related
- 2005-10-20 CA CA2585053A patent/CA2585053C/en not_active Expired - Fee Related
- 2005-10-20 ES ES05815361.0T patent/ES2611604T3/es not_active Expired - Lifetime
- 2005-10-20 UA UAA200704498A patent/UA88648C2/ru unknown
- 2005-10-20 HU HUE05815361A patent/HUE033089T2/en unknown
- 2005-10-20 MX MX2007004784A patent/MX2007004784A/es active IP Right Grant
- 2005-10-20 AU AU2005299837A patent/AU2005299837A1/en not_active Abandoned
- 2005-10-20 DK DK05815361.0T patent/DK1807077T3/en active
- 2005-10-20 PL PL05815361T patent/PL1807077T3/pl unknown
- 2005-10-20 EA EA200700918A patent/EA013250B1/ru not_active IP Right Cessation
- 2005-10-20 BR BRPI0516947-0A patent/BRPI0516947A/pt not_active Application Discontinuation
-
2007
- 2007-05-15 NO NO20072489A patent/NO339555B1/no not_active IP Right Cessation
- 2007-05-21 ZA ZA200704106A patent/ZA200704106B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517926A5 (https=) | ||
| CA2585053A1 (en) | Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors | |
| JP2008517945A5 (https=) | ||
| JP2024513881A5 (https=) | ||
| EP1396487B1 (en) | Phenylpyridine carbonyl piperazine derivative | |
| JP2011515462A5 (https=) | ||
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2014511869A5 (https=) | ||
| JP2005533803A5 (https=) | ||
| JP2017502940A5 (https=) | ||
| JP2013510876A5 (https=) | ||
| JP2003502405A5 (https=) | ||
| JP2004504301A5 (https=) | ||
| JP2009541268A5 (https=) | ||
| JP2006500348A5 (https=) | ||
| JP2005513123A5 (https=) | ||
| JPWO2020009156A5 (https=) | ||
| JP2012530765A5 (https=) | ||
| RU2006126974A (ru) | Амидное производное и лекарственное средство | |
| JP2006507247A5 (https=) | ||
| JP2017536342A5 (https=) | ||
| RU2005103618A (ru) | Ингибирующие циклооксигеназу-2 (цог-2) производные пиридина | |
| JP2010527985A5 (https=) | ||
| JP2008513405A5 (https=) | ||
| JP2007506703A5 (https=) |